Landmark Study Reveals Magnitude of Uncertain Results in Clinical Genetic Testing for Hereditary Disease, Points to Evidence-Based Solutions to Reach Definitive Results

– Findings set to enhance patient care and reduce uncertainty in test results as clinicians advance precision healthcare for hereditary disease – SAN FRANCISCO, Oct. 25, 2023 /PRNewswire/ — Invitae (NYSE: NVTA), a leading medical genetics company, today announced findings from the…

Click here to view original post